Description

Simple

A medication used to relieve heartburn and indigestion.

Clinical

An antacid used for the symptomatic treatment of peptic ulcers.

Overview

Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.

Pharmacology

Indication

For the treatment of peptic ulcers.
Relieving indigestion and heartburn.

Pharmacodynamic

Magnesium trisilicate works by increasing the pH of gastric juice via a neutralisation reaction. It also precipitates colloidal silica, which can coat gastrointestinal mucosa conferring further protection.

Mechanism of action

The gelatinous silicon dioxide, formed by the reaction of magnesium trisilicate with gastric contents is said to protect ulcerated mucosal surfaces and favor healing.

Absorption

The hydrated silicon dioxide formed in the stomach and passes into the intestinal track where, silica can be partly absorbed.

Protein binding

33%

Volume of distribution

The hydrated silicon dioxide formed in the stomach and passes into the intestinal track.

Clearance

Maximum magnesium clearance is directly proportional to creatinine clearance.

Half life

16-20 hours

Route of elimination

Excreted in the urine.

Toxicity

Adequate doses of magnesium trisilicate may cause diarrhea due to the action of soluble magnesium salts in the enteric tract. Approx 5% of the magnesium is absorbed.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Magnesium trisilicate
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1alpha-Hydroxyvitamin D5
The serum concentration of Magnesium trisilicate can be increased when it is combined with 1alpha-Hydroxyvitamin D5.
1alpha,24S-Dihydroxyvitamin D2
The serum concentration of Magnesium trisilicate can be increased when it is combined with 1alpha,24S-Dihydroxyvitamin D2.
2,5-Dimethoxy-4-ethylamphetamine
The serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be increased when it is combined with Magnesium trisilicate.
2,5-Dimethoxy-4-ethylthioamphetamine
The serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be increased when it is combined with Magnesium trisilicate.
3-Aza-2,3-Dihydrogeranyl Diphosphate
Magnesium trisilicate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
4-Bromo-2,5-dimethoxyamphetamine
The serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be increased when it is combined with Magnesium trisilicate.
Abacavir
Abacavir may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Abafungin
Magnesium trisilicate can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acarbose
Acarbose may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Aceclofenac
Aceclofenac may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Acemetacin
Acemetacin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Acepromazine
Magnesium trisilicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aceprometazine
Magnesium trisilicate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetaminophen
Magnesium trisilicate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetazolamide
The risk or severity of adverse effects can be increased when Acetazolamide is combined with Magnesium trisilicate.
Acetophenazine
Magnesium trisilicate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetyldigoxin
The serum concentration of Acetyldigoxin can be decreased when it is combined with Magnesium trisilicate.
Acetylsalicylic acid
Acetylsalicylic acid may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Aclidinium
Aclidinium may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Acrivastine
Magnesium trisilicate may decrease the excretion rate of Acrivastine which could result in a higher serum level.
3 References
  1. 1 . Toxnet Link
  2. 2 . Toxnet Link
  3. 3 . Sciencedirect Link